Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity

Daniel Josef Pham, Ann Thompson, Tomas Kron, Farshad Foroudi, Michal E Schneider, Thomas Devereux, Andrew Lim, Shankar Siva

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)


PURPOSE: To describe our 3-dimensional conformal planning approaches and report early toxicities with stereotactic body radiation therapy for the management of primary renal cell carcinoma. METHODS AND MATERIALS: This is an analysis of a phase 1 trial of stereotactic body radiation therapy for primary inoperable renal cell carcinoma. A dose of 42 Gy/3 fractions was prescribed to targets >/=5 cm, whereas for 100 cm(3) the median beam number used was 10 (4 noncoplanar) for an average R50 value of 4.3. The R50 was inversely proportional to decreasing PTV volume (r=-0.62, P=.003) and increasing total beams used (r=-0.51, P=.022). Twelve of 20 patients (60 ) suffered grade
Original languageEnglish
Pages (from-to)1061 - 1068
Number of pages8
JournalInternational Journal of Radiation Oncology, Biology, Physics
Issue number5
Publication statusPublished - 2014

Cite this